<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663949</url>
  </required_header>
  <id_info>
    <org_study_id>3079</org_study_id>
    <nct_id>NCT00663949</nct_id>
  </id_info>
  <brief_title>Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy</brief_title>
  <official_title>Phase 2 Trial of Effect of Combine Pentoxifylline and Captopril on Proteinuria in Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic nephropathy is the most common cause of ESRD and has a great impact on mortality and
      morbidity of diabetic patients. Despite renoprotective effect of ACE inhibitors in diabetic
      patients they can not hinder the progression of renal disease completely. Pentoxifylline as a
      TNFa blocker may hinder progression of diabetic nephropathy in combination of captopril.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic nephropathy is the most common cause of ESRD and has a great impact on mortality and
      morbidity of diabetic patients. Despite renoprotective effect of ACE inhibitors in diabetic
      patients they can not hinder the progression of renal disease completely. TNFa is a cytokine
      that is a target for medical therapy in diabetic nephropathy. In this study the effect of
      captopril on overt diabetic nephropathy compared to effect of combination of captopril and an
      antiTNFa drug ( pentoxifylline).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>decreasing urinary protein</measure>
    <time_frame>2 and 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>A,1,II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in this arm takes 25 mg captopril q8h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A,2,II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Captopril</intervention_name>
    <description>25 mg captopril tablet q8h</description>
    <arm_group_label>A,1,II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Captopril + Pentoxifylline</intervention_name>
    <description>patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h</description>
    <arm_group_label>A,2,II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Absence of kidney or urinary tract disease

          2. Absence of high blood pressure OR Controlled blood pressure (≤140/90) with medication
             other than ACE inhibitors and/or non dihydropyridine calcium channel blockers

          3. A well controlled blood sugar level (HbA1c≤7.5%)

          4. Adhering to the diet protocol for patients with renal disease

        Exclusion Criteria:

          1. NYHA functional class III, IV

          2. Valvular heart disease

          3. Unstable angina, myocardial infarction, cerebrovascular accidents

          4. Psychiatric disease

          5. Prior allograft kidney transplant

          6. Acute illness

          7. Infectious disease including urinary tract infection

          8. Leukocytosis or any febrile illness at enrollment

          9. Prior history or development of any form of malignancy

         10. History of alcohol or drug abuse or smoking

         11. Pregnancy

         12. Need for surgery during the study

         13. Allergy to derivatives of methyl xanthines

         14. Current Pentoxyphilline use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamshid Roozbeh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>sums</affiliation>
  </overall_official>
  <overall_official>
    <last_name>mohammad ghezloo, MD</last_name>
    <role>Study Director</role>
    <affiliation>SUMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>mohammad mahdi sagheb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amin Banihashemi</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shiraz University of Medical Sciences ,Nemazee and Faghihi Hospital</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>0098</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <last_update_submitted>April 21, 2008</last_update_submitted>
  <last_update_submitted_qc>April 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>shiraz university of medical sciences vice chancellor for research</name_title>
    <organization>SUMS</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>proteinuria</keyword>
  <keyword>pentoxifylline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
    <mesh_term>Captopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

